These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25717286)

  • 1. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.
    Yamada N; Hirayama A; Maeda H; Sakagami S; Shikata H; Prins MH; Lensing AW; Kato M; Onuma J; Miyamoto Y; Iekushi K; Kajikawa M
    Thromb J; 2015; 13():2. PubMed ID: 25717286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
    Wang Y; Wang C; Chen Z; Zhang J; Liu Z; Jin B; Ying K; Liu C; Shao Y; Jing Z; Meng IL; Prins MH; Pap AF; Müller K; Lensing AW;
    Thromb J; 2013 Dec; 11(1):25. PubMed ID: 24341332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
    Prins MH; Lensing AW; Bauersachs R; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Raskob GE; Berkowitz SD; Wells PS;
    Thromb J; 2013 Sep; 11(1):21. PubMed ID: 24053656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
    Wells PS; Gebel M; Prins MH; Davidson BL; Lensing AW
    Thromb J; 2014; 12():26. PubMed ID: 25698905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
    Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
    Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients.
    Nakamura M; Okano Y; Minamiguchi H; Munemasa M; Sonoda M; Yamada N; Hanzawa K; Aoyagi N; Tsujimoto H; Sarai N; Nakajima H; Kunieda T
    Circ J; 2011; 75(6):1424-32. PubMed ID: 21512258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.
    Zidane M; Schram MT; Planken EW; Molendijk WH; Rosendaal FR; van der Meer FJ; Huisman MV
    Arch Intern Med; 2000 Aug 14-28; 160(15):2369-73. PubMed ID: 10927736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Haupt V; Schneider J; Turpie AG
    Thromb J; 2014; 12():16. PubMed ID: 25093014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.
    Migita S; Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    Thromb J; 2023 Aug; 21(1):88. PubMed ID: 37599351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
    Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
    BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.